Jessica K Altman
Jessica K Altman is associate professor in medicine — hematology/oncology at Robert H Lurie Comprehensive Cancer Center and division of hematology/oncology, Northwestern University Medical School, Chicago, IL 60611.
While the initial therapy for acute myeloid leukaemia (AML) treatment is relatively standardised, the high incidence of refractory/relapsed disease remains a great challenge. Progress has been made in understanding the pathophysiology of both initial and recurrent disease phases, leading to rigorous pre-clinical studies to identify and selectively target cellular pathways that promote leukaemogenesis. In this article, we discuss the ongoing efforts in overcoming relapsed disease, through a l